

# Luis Eduardo LÃ³pez-CortÃ©s

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6868144/publications.pdf>

Version: 2024-02-01

56  
papers

1,055  
citations

567281

15  
h-index

454955

30  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1340  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ceftobiprole, a new option for multidrug resistant microorganisms in the outpatient antimicrobial therapy setting. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2022, 40, 399-400.	0.5	1
2	Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 550-557.	6.0	62
3	Impact of neutropenia on clinical manifestations and outcome of <i>Staphylococcus aureus</i> bloodstream infection: a propensity score-based overlap weight analysis in two large, prospectively evaluated cohorts. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1149.e1-1149.e9.	6.0	2
4	Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT. <i>Journal of Clinical Medicine</i> , 2022, 11, 1551.	2.4	3
5	Ampicillin Plus Ceftriaxone Combined Therapy for <i>Enterococcus faecalis</i> Infective Endocarditis in OPAT. <i>Journal of Clinical Medicine</i> , 2022, 11, 7.	2.4	11
6	Stability of Antimicrobials in Elastomeric Pumps: A Systematic Review. <i>Antibiotics</i> , 2022, 11, 45.	3.7	11
7	<i>Pseudomonas aeruginosa</i> Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Developmentâ€”Results from the PRO-BAC Cohort. <i>Antibiotics</i> , 2022, 11, 707.	3.7	1
8	Risk of cardiac device-related infection in patients with late-onset bloodstream infection. Analysis on a National Cohort. <i>Journal of Infection</i> , 2022, 85, 123-129.	3.3	3
9	Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> : a Multicenter Cohort Study from the PROBAC Project. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	3
10	Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. <i>PLoS ONE</i> , 2022, 17, e0269875.	2.5	0
11	Enterococcal Endocarditis: Relapses or Reinfections?. <i>Clinical Infectious Diseases</i> , 2021, 72, 360-361.	5.8	5
12	Relevance of intra-hospital patient movements for the spread of healthcare-associated infections within hospitals - a mathematical modeling study. <i>PLoS Computational Biology</i> , 2021, 17, e1008600.	3.2	15
13	Clinical Features and Outcomes of <i>Streptococcus anginosus</i> Group Infective Endocarditis: A Multicenter Matched Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab163.	0.9	7
14	Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study. <i>PLoS ONE</i> , 2021, 16, e0250796.	2.5	17
15	Impact of Immunosuppressive Agents on Clinical Manifestations and Outcome of <i>Staphylococcus aureus</i> Bloodstream Infection: A Propensity Scoreâ€”Matched Analysis in 2 Large, Prospectively Evaluated Cohorts. <i>Clinical Infectious Diseases</i> , 2021, 73, 1239-1247.	5.8	4
16	Blood culture-negative infective endocarditis: a worse outcome? Results from a large multicentre retrospective Spanish cohort study. <i>Infectious Diseases</i> , 2021, 53, 755-763.	2.8	8
17	Analysis of sex differences in the clinical presentation, management and prognosis of infective endocarditis in Spain. <i>Heart</i> , 2021, 107, 1717-1724.	2.9	15
18	Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106352.	2.5	9

#	ARTICLE	IF	CITATIONS
19	Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant <i>Enterobacterales</i> (ASTART3): protocol for a randomised, pragmatic trial. <i>BMJ Open</i> , 2021, 11, e049481.	1.9	6
20	An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 730-737.	3.0	17
21	Antifungal treatment administered in OPAT programs is a safe and effective option in selected patients. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2020, 38, 479-484.	0.5	5
22	<i>Enterococcus faecalis</i> Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives. <i>Antibiotics</i> , 2020, 9, 657.	3.7	15
23	Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for <i>Enterococcus faecalis</i> Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	8
24	Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 303%day mortality in a multicentre prospective cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3056-3061.	3.0	12
25	Characteristics and Outcomes of <i>Staphylococcus aureus</i> Bloodstream Infection Originating From the Urinary Tract: A Multicenter Cohort Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa216.	0.9	7
26	Therapy of <i>Staphylococcus aureus</i> bacteremia: Evidences and challenges. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2020, 38, 489-497.	0.5	8
27	Dysfunctional accessory gene regulator ( <i>agr</i> ) as a prognostic factor in invasive <i>Staphylococcus aureus</i> infection: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 20697.	3.3	15
28	Defining persistent <i>Staphylococcus aureus</i> bacteraemia: secondary analysis of a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1409-1417.	9.1	84
29	Sequential antimicrobial therapy in mediastinitis after cardiac surgery: An observational study of 81 cases. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2020, 38, 361-366.	0.5	0
30	Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus</i> infective endocarditis. <i>BMC Infectious Diseases</i> , 2020, 20, 160.	2.9	17
31	A Contemporary Picture of Enterococcal Endocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 482-494.	2.8	49
32	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. <i>Critical Care</i> , 2020, 24, 117.	5.8	19
33	Antifungal treatment administered in OPAT programs is a safe and effective option in selected patients. <i>Enfermedades Infecciosas Y Microbiologia Cl3nica (English Ed)</i> , 2020, 38, 479-484.	0.3	1
34	Therapy of <i>Staphylococcus aureus</i> bacteremia: Evidences and challenges. <i>Enfermedades Infecciosas Y Microbiologia Cl3nica (English Ed)</i> , 2020, 38, 489-497.	0.3	0
35	Outpatient Parenteral Antimicrobial Treatment for Non-Cystic Fibrosis Bronchiectasis Exacerbations: A Prospective Multicentre Observational Cohort Study. <i>Respiration</i> , 2019, 98, 294-300.	2.6	7
36	DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2019, 18, 30.	3.8	71

#	ARTICLE	IF	CITATIONS
37	Moving beyond unsolicited consultation: additional impact of a structured intervention on mortality in <i>Staphylococcus aureus</i> bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1101-1107.	3.0	18
38	Role of age and comorbidities in mortality of patients with infective endocarditis. <i>European Journal of Internal Medicine</i> , 2019, 64, 63-71.	2.2	43
39	Impact of infectious diseases consultation on the outcome of patients with bacteraemia. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611989357.	1.8	6
40	Next Step, Outpatient Antimicrobial Therapy Programs as a Tool of Stewardship Programs. <i>Clinical Infectious Diseases</i> , 2019, 68, 2155-2155.	5.8	5
41	Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort. <i>Clinical Infectious Diseases</i> , 2019, 69, 1690-1700.	5.8	44
42	Infective endocarditis: New forms of the disease, new therapeutic options. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2019, 37, 425-427.	0.5	1
43	In ReplyStatin Use Associated With a Decreased Risk of Community-Acquired <i>Staphylococcus aureus</i> Bacteremia. <i>Mayo Clinic Proceedings</i> , 2018, 93, 542.	3.0	0
44	Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 555-562.	1.7	21
45	LB3. Daptomycin Plus Fosfomycin vs. Daptomycin Monotherapy for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: A Multicenter, Randomized, Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S760-S760.	0.9	4
46	Survival following <i>Staphylococcus aureus</i> bloodstream infection: A prospective multinational cohort study assessing the impact of place of care. <i>Journal of Infection</i> , 2018, 77, 516-525.	3.3	48
47	Infective Endocarditis in Patients With Bicuspid Aortic Valve or MitralValveProlapse. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2731-2740.	2.8	65
48	How should we best treat patients with bloodstream infections?. <i>Future Microbiology</i> , 2017, 12, 927-930.	2.0	9
49	Statin Use and Risk of Community-Acquired <i>Staphylococcus aureus</i> Bacteremia: A Population-Based Case-Control Study. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1469-1478.	3.0	20
50	Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to <i>Enterobacteriaceae</i> (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial. <i>BMJ Open</i> , 2017, 7, e015439.	1.9	7
51	Reply to Fries et al and Valentin et al. <i>Clinical Infectious Diseases</i> , 2014, 58, 600-601.	5.8	0
52	Impact of an Evidence-Based Bundle Intervention in the Quality-of-Care Management and Outcome of <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 57, 1225-1233.	5.8	192
53	Effect of Statin Therapy in the Outcome of Bloodstream Infections Due to <i>Staphylococcus aureus</i> : A Prospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e82958.	2.5	28
54	Daptomycin or Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> with a Vancomycin Minimum Inhibitory Concentration >1 g/L. <i>Clinical Infectious Diseases</i> , 2012, 54, 1375-1376.	5.8	2

#	ARTICLE	IF	CITATIONS
55	Diabetes mellitus tipo 2 descompensada y disfuncin renal en paciente con trasplante cardiaco en tratamiento inmunosupresor. Avances En Diabetologa, 2012, 28, 32-34.	0.1	0
56	Numb chin syndrome: A warning sign of aggressive B-cell malignancy. Leukemia Research, 2011, 35, e177-e178.	0.8	2